Ensign Peak Advisors
CAPR icon

Ensign Peak Advisors’s Capricor Therapeutics CAPR Stock Holding History

Ensign Peak Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.6K Buy
3,100
+1,800
+138% +$54.6K ﹤0.01% 1674
2026
Q1 		$39.5K Buy
+1,300
New +$34.6K ﹤0.01% 1688

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ensign Peak Advisors's CAPR Position: Q2 2026 in Review

Ensign Peak Advisors increased its Capricor Therapeutics (CAPR) stake by 138% in Q2 2026, buying an estimated $54.6K and bringing the position to 3,100 shares worth $74.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1674.

Ensign Peak Advisors first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Ensign Peak Advisors held 3,100 shares of Capricor Therapeutics worth $74.6K as of Q2 2026.
  • Ensign Peak Advisors bought 1,800 Capricor Therapeutics shares in Q2 2026, an estimated $54.6K.
  • Capricor Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1674 holding.
  • Ensign Peak Advisors first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.